I-Molnupiravir N-1 CAS 2346620-55-9 COVID-19 Umgangatho oPhezulu
Ubonelelo ngezoRhwebo i-Molnupiravir kunye neMidiya eNxulumene nayo enoMgangatho oPhezulu
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
I-Molnupiravir N-1 CAS 2346620-55-9
I-Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Igama leMchiza | I-Molnupiravir N-1 |
| Izithethantonye | ((3aR,4R,6R,6aR)-6-(E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3, 4-d][1,3]dioxol-4-yl)methyl isobutyrate;I-Molnupiravir ePhakathi;I-Molnupiravir Dimethyl Dioxol Ukungcola;Ukungacoceki kweMolnupiravir 11 |
| Inombolo yeCAS | 2346620-55-9 |
| Inombolo yeCAT | RF-PI310 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | C16H23N3O7 |
| Ubunzima beMolekyuli | 369.37 |
| Ukunyibilika | Inyibilika kwi-DMSO |
| Ukuxinana | 1.51±0.1 g/cm3 |
| Ubushushu bokuthutha | I-Ambient |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder |
| Ilahleko ekomisweni | ≤1.0% |
| Intsalela kwi-Ignition | ≤0.20% |
| Ukungacoceki Okukodwa | ≤0.50% |
| Ukungcola ngokupheleleyo | ≤2.0% |
| Iintsimbi ezinzima | ≤20ppm |
| Ubunyulu | ≥98.0% |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | Umbindi we-Molnupiravir (CAS 2349386-89-4) COVID-19 |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Molnupiravir N-1 (CAS 2346620-55-9), yindawo ephakathi ye-Molnupiravir (CAS 2349386-89-4) kunyango lwe-COVID-19.I-Molnupiravir (EIDD-2801) luhlobo olufumaneka ngomlomo lwe-ribonucleoside analog ethintela ukuphindaphinda kweentsholongwane ezininzi ze-RNA kubandakanya i-SARS-CoV-2, eyona arhente ibangela i-COVID-19.I-EIDD-2801 (7 mg / kg; po; kabini imihla ngemihla ngeentsuku ze-3.5) iyanciphisa kakhulu i-virus echithiweyo kunye nobude befiva.I-Molnupiravir (EIDD-2801) ifakwe ngokufanelekileyo i-hydrolyzed kwi-vivo emva kokufunxa, okukhokelela ekubhaqweni kwe-NHC yasimahla kuphela kwiplasma.I-EIDD-2801 inciphisa ngamandla i-MERS-CoV i-infectious titers, i-RNA ye-viral, kunye ne-pathogenesis phantsi kweemeko zombini ze-prophylactic kunye neemeko zokuqala zonyango.I-Molnupiravir (EIDD-2801, MK-4482) yimveliso yomlomo ye-bioavailable ye-ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) kunye nomsebenzi we-antiviral obanzi ngokuchasene ne-SARS-CoV-2, i-MERS-CoV, I-SARS-CoV, kunye ne-arhente ebangela i-COVID-19.
